(MENAFN- GlobeNewsWire - Nasdaq) Lung transplant rejection is a critical challenge in transplantation medicine, with the patient's immune system attacking transplanted tissue, potentially leading to graft failure. This can occur in three main phases: hyperacute, acute, and chronic rejection. Causes include mismatched HLA types, infections, and inflammation, with symptoms like shortness of breath and fever. Advancements in immunosuppressive therapies and diagnostics, including biomarkers and non-invasive tests, are enhancing early detection and treatment. The global market is growing, driven by innovations in personalized medicine and lung preservation technologies, despite challenges like high drug costs.

Dublin, Nov. 19, 2025 (GLOBE NEWSWIRE) -- The "Lung Transplant Rejection Market - A Global and Regional Analysis: Focus on Country and Region - Analysis and Forecast, 2025-2035" report has been added to ResearchAndMarkets's offering.
The global lung transplant rejection market is expanding, driven by rising awareness of lung transplant complications, increasing demand for effective rejection prevention strategies, and ongoing research into better immunosuppressive therapies. Innovations in immunosuppressive drugs, are improving graft survival and reducing the likelihood of rejection.

Moreover, the development of induction therapy and steroid-sparing regimens is making immunosuppressive treatment safer and more effective, minimizing side effects such as infection and organ toxicity. The use of targeted therapies, based on genetic and immunological profiling, is allowing for more personalized treatment regimens, improving both graft survival rates and quality of life for recipients.

Additionally, advances in lung preservation technologies, such as ex vivo lung perfusion (EVLP) and normothermic perfusion, are improving the viability of donor lungs, further reducing the risk of rejection. Despite these advancements, the lung transplant rejection market faces several challenges. One of the major barriers is the high cost of immunosuppressive drugs.
Key players in the lung transplant rejection market include TFF Pharmaceuticals, Inc., and Astellas Pharma. These companies are investing heavily in research and development to improve existing immunosuppressive therapies, develop new biologics, and explore innovative approaches to prevent rejection and enhance graft survival. Strategic collaborations between pharmaceutical companies, academic research institutions, and transplant centers are accelerating efforts to find more effective treatments and improve patient outcomes. Additionally, partnerships with regulatory bodies and non-profit organizations are promoting awareness and improving donor organ procurement, which could help reduce rejection rates and improve survival outcomes.
The competitive landscape of the lung transplant rejection market is shaped by the presence of both large pharmaceutical companies and specialized biotech firms, all working to address the unmet needs in transplant rejection prevention and management. Smaller companies are focusing on niche areas, such as gene therapies, immune modulation, and biomarker development, which could potentially revolutionize the approach to lung transplant rejection.

As research into immune tolerance and novel drug delivery systems continues, the market is expected to diversify with more targeted and efficient therapies. Collaborations between drug developers, healthcare providers, and patient advocacy organizations will be essential in improving access to therapies and advancing the treatment of lung transplant rejection globally.
With expanding healthcare infrastructure in emerging markets and improved diagnostic tools for early detection, the lung transplant rejection market is positioned for continued growth, supported by ongoing research and advancements in prevention and treatment.
Key Topics Covered:
Executive Summary
Scope and Definition
Market/Product Definition
Inclusion and Exclusion
Key Questions Answered
Analysis and Forecast Note
1. Global Lung Transplant Rejection Market: Industry Analysis
1.1 Market Overview and Ecosystem
1.2 Epidemiological Analysis
1.3 Key Market Trends
1.4 Regulatory Landscape
1.5 Pipeline Analysis
1.6 Market Dynamics
1.6.1 Impact Analysis
1.6.2 Market Drivers
1.6.3 Market Restraints
1.6.4 Market Opportunities
2. Global Lung Transplant Rejection Market, Region, $Million, 2024-2035
2.1 North America
2.1.1 Market Dynamics
2.1.2 Market Sizing and Forecast
2.1.2.1 North America Lung Transplant Rejection Market, by Country ($ Million), 2024-2035
2.1.2.2 U.S.
2.2 Europe
2.2.1 Market Dynamics
2.2.2 Market Sizing and Forecast
2.2.2.1 Europe Lung Transplant Rejection Market, by Country ($ Million), 2024-2035
2.2.2.1.1 U.K.
2.2.2.1.2 France
2.2.2.1.3 Germany
2.2.2.1.4 Italy
2.2.2.1.5 Spain
2.3 Asia-Pacific
2.3.1 Market Dynamics
2.3.2 Market Sizing and Forecast
2.3.2.1 Asia-Pacific Lung Transplant Rejection Market, by Country ($ Million), 2024-2035
2.3.2.1.1 Japan
2.4 Rest-of-the-World
2.4.1 Market Dynamics
2.4.2 Market Sizing and Forecast
3. Global Lung Transplant Rejection Market: Competitive Landscape and Company Profiles
3.1 Competitive Landscape
3.1.1 Mergers and Acquisitions
3.1.2 Partnership, Alliances and Business Expansion
3.1.3 New Offerings
3.1.4 Regulatory Activities
3.1.5 Funding Activities
3.2 Company Profiles
3.2.1 Astellas Pharma Inc.
3.2.1.1 Overview
3.2.1.2 Top Products / Product Portfolio
3.2.1.3 Top Competitors
3.2.1.4 Target Customers/End-Users
3.2.1.5 Key Personnel
3.2.1.6 Analyst View
3.2.2 TFF Pharmaceuticals, Inc.
3.2.2.1 Overview
3.2.2.2 Top Products / Product Portfolio
3.2.2.3 Top Competitors
3.2.2.4 Target Customers/End-Users
3.2.2.5 Key Personnel
3.2.2.6 Analyst View
3.2.3 Others
4. Research Methodology

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN19112025004107003653ID1110367851